



Scholars Research Library
Central European Journal of Experimental
Biology, 2012, 1 (2):53-61
(<http://scholarsresearchlibrary.com/archive.html>)



***In vitro* antibacterial efficacy of crude ethanolic leaf extract and alkaloidal fractions of *Phyllanthus Amarus* on uro-pathogens**

¹Akinjogunla, Olajide J, ²Bala, Danladi N. and ¹Sylvester, Maria A.

¹Department of Microbiology, Faculty of Science, University of Uyo, P.M.B. 1017, Uyo, Akwa Ibom State.

²Department of Pharmacognosy and Natural Medicine, Faculty of Pharmacy, University of Uyo, P.M.B. 1017, Uyo, Akwa Ibom State.

ABSTRACT

The phytochemistry and *in vitro* antibacterial efficacy of crude ethanolic leaf extract and alkaloidal fractions of *Phyllanthus amarus* on the Gram positive (*Streptococcus* sp, *Staphylococcus aureus*; Coagulase negative *Staphylococcus* sp and *Enterococcus faecalis*) and Gram negative bacteria (*Escherichia coli*, *Enterobacter* sp.; *Serratia marcescens*; *Klebsiella* sp and *Pseudomonas aeruginosa*) isolated from mid stream urine were carried out using standard microbiological and disc diffusion techniques. The preliminary phytochemical analysis of the ethanolic leaf extracts of *P. amarus* revealed the presence of phyto-constituents such as alkaloids (+++), tannins (+++), saponins (++), flavonoids (++), cardiac glycoside (+), free anthraquinones (++), deoxy-Sugar test (+) and phlobatanins (+), while combined anthraquinones was not detected. The results showed that *P. amarus* extracts exhibited varying degrees of inhibitory effects against both Gram positive and Gram negative bacteria isolated from urine samples. Highest mean zones of inhibition (14.3 ± 1.0 mm) and activity index (0.97) were obtained at 40.0 mg ml^{-1} among the Gram positive bacteria, while the highest mean zones of inhibition ($14.5 \pm 0.5 \text{ mm}$) and activity index (1.12) at 40.0 mg ml^{-1} were obtained among the Gram negative. The results also showed that Coagulase negative *Staphylococcus* sp (CS03) was not sensitive to both 20.0 mg ml^{-1} of crude extracts of *P. amarus* and alkaloidal fractions. Among the Gram negative, *Enterobacter* sp (ES03) was not sensitive to 20.0 mg ml^{-1} of crude extracts of *P. amarus*, alkaloidal fractions and Streptomycin. Therefore, there is a need to consider the use of this potent ethanolic leaf extracts and the alkaloids for developing synthetic drugs against uro-pathogens.

Keywords: *Phyllanthus amarus*, uro-pathogens, alkaloids, urine, antibacterial.

INTRODUCTION

Urinary tract infections (UTIs) are caused by pathogenic invasion of the urinary tract, which lead to an inflammation of the urothelium [1]. Urinary tract infections are the most frequently diagnosed cases, having an estimated figure of 150 million per annum worldwide [2]. Urinary tract infections are the most commonly observed infection in many hospitals, and accounts for approximately 35% of all hospital acquired diseases [3]. The clinical manifestations of UTI depend on the portion of the urinary tract involved, the etiologic organisms, the severity of the infection, and the patient's ability to mount an immune response to it [1]. The common uro-pathogens identified in patients with urinary tract infections were Gram negative such as *Escherichia coli*, *Proteus* sp, *Klebsiella* sp and *Pseudomonas*

aeruginosa [4, 5, 6], while the Gram positive bacteria were *Staphylococcus aureus* and coagulase *Staphylococcus* sp [2]. *Escherichia coli* causes 85% of community acquired urinary tract infections and more than 80% of cases of uncomplicated pyelonephritis [7]. The prevalence and incidence of urinary tract infection is higher in women than in men, which is likely the result of several clinical factors including anatomic differences, hormonal effects, and behavioural patterns [1, 8]. In spite of the availability and use of the antimicrobial drugs, urinary tract pathogens caused by bacteria have shown increasing trends in recent years. Much of the increase has been related to emerging antibiotic resistance in urinary tract pathogens and the emergence of multi-drug resistant bacteria is of great concern to both clinicians and the pharmaceutical industry, since it is a major cause of treatment failure in many infectious diseases [9,10]. Thus, it is necessary to search for alternative antimicrobial agents.

Plants have provided a source of inspiration for novel drug compounds, as plant derived medicines have made large contributions to human health and well being [11,12]. Traditional medicine using plant extracts continues to provide health coverage for approximately 80% of the world's population and is still much practiced by a large proportion of the rural populace especially those in low income world population because of its availability and affordability [12, 13]. *Phyllanthus amarus*, an erect annual herb of not more than one and half feet tall and has small leaves and yellow flowers belongs to the family Euphorbiaceae. It was first identified in central and Southern India in 18th century. It is commonly called "carry me seed", or "gulf leaf flower", "hurricane weed", "windbreaker", [14]. There are over 300 genera with over 5000 species in the Euphorbiaceae worldwide. *Phyllanthus amarus* has reportedly been used to treat jaundice, otitis, diarrhoea, skin ulcer, diabetes, hypertension and gastrointestinal disturbances and block DNA polymerase in the case of hepatitis B virus during reproduction [15,16,17]. Consequently, the aim of this study is to determine the in-vitro efficacy of crude ethanolic leaf extract and alkaloidal fractions of *P. amarus* on uro-pathogens.

MATERIALS AND METHODS

Source and Extraction of Plant

The leaves of *P. amarus* were collected in Uyo, Akwa Ibom State. The taxonomic identification of the plants was done at the Department of Botany and Ecological Studies, University of Uyo, Akwa Ibom State. The plant was washed under running tap water and with distilled water in order to remove extraneous matters and air-dried at room temperature for one month. The dried plant part was pulverized in a mill and stored in polythene bag until required. The powdered *P. amarus* was exhaustively extracted by Soxhlet Apparatus using 95% ethanol. The filtrate was evaporated using a rotary evaporator attached to a vacuum pump. After complete evaporation, the extract was thereafter transferred into weighed bottle which was properly labelled with dates and stored in the refrigerator at 4°C until required for used. The graded concentrations (20 mgml⁻¹ and 40 mgml⁻¹) of the extract were prepared using Dimethyl sulphoxide (DMSO) and then subjected to antibacterial assays.

Sterilization of Materials

The Petri dishes and pipettes packed into metal canisters were appropriately sterilized in the hot air oven at 180°C for 2hrs at each occasion. The culture media were autoclaved at 121°C for 15mins.

Source of Bacterial Isolates

The bacterial isolates used were: *Staphylococcus aureus*, Coagulase negative *Staphylococcus* spp, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Serratia marcescens*, *Pseudomonas aeruginosa*, *Escherichia coli*. *Proteus mirabilis*, *Klebsiella* spp. and *Enterobacter* spp. These species were freshly isolated from clinical specimens (midstream-urine) and identified using routine conventional laboratory techniques including Gram staining, motility, coagulase, catalase, oxidase, indole, urease production, citrate utilization, methyl red, Vogues Proskauer. Carbohydrate fermentation tests such as mannitol, sucrose, glucose and lactose were also carried out using the methods described by [18,19, 20]. Stock cultures were maintained on nutrient agar slant at 4°C until needed.

Phytochemical Screening (Quantitative)

Test for Alkaloids

Half a gram (0.5g) of the plant extracts was stirred with 5ml in 5% Hydrochloric Acid (HCl) on a steam bath and then filtered 1ml of the filtrate was treated with a few drop of Mayer's reagent and a second 1ml portion was treated similarly with Dragendorff's reagent, turbidity or precipitation of cream and pink or red colouration respectively indicated in positive test. The their 1ml portion was treated with a few drops of picric acid while yellow precipitate was taken as preliminary evidence for the presence of alkaloids

Test for Saponins

(a) **Frothing Test:** Half a gram (0.5g) of each extract was shaken vigorously with distilled water in a test tube, frothing that persisted on warning was taken as preliminary evidence for the presence of saponins.

(b) **Sodium Bicarbonate Test:** Half a gram (0.5g) of each extract was added with 5% sodium bicarbonate and Fehling's solution A and B and boiled. Presence of brown precipitate was termed as a positive test.

Test for Tannins

(a) **Ferric chloride test:** Half a gram (0.5g) of each plant extract was stirred with 10mls of distilled water and filtered; to the filtrate 5% Ferric chloride reagent was added. A blue-black green or blue-green precipitate was taken as evidence for the presence of tannins.

(b) **Bromine water test:** Five (5) drops of each plant extract solution as mixed with 10ml distilled water and bromide water. Decolourization of bromine water indicated the presence of tannins.

Test for Anthraquinones

(a) **Borntrager's test for the free hydroxyanthraquinones.**

Half a gram (0.5g) of plant extract was shaken with 10ml benzene and filtered. To the filtrate were added 10% ammonia solution and the mixture shaken. The presence of a pink, red or violet colour in the ammonical (lower) phase indicated the presence of free anthraquinones.

(b) **Borntrager's test for combine anthraquinones**

Half a gram (0.5g) of plant extract was boiled with 10ml dilute sulphuric acid and filtered. The filtrate was shaken with 5ml benzene and 10% ammonia solution was added to the separate benzene layer. A pink red or violet colouration in the ammonia (lower) layer indicated the presence of anthraquinones derivative.

Test for Flavonoids

Shinoda Reduction Test: Few pieces of magnesium metal were added to 5ml of each plant extract solution. The solution was obtained by using concentrated hydrochloric acid to dissolve the extract. The formation of orange, red crimson or magenta colouration was taken as evidence of preliminary presence of flavonoids.

Test for Cardiac Glycosides

(a) **Salkowski's Test:** Half a gram (0.5g) of extract was dissolved in 2ml of chloroform. Concentrated sulphuric acid was carefully added by running it down the side of the test tube. A reddish brown colour at the interphase indicated the presence of glycon portion of cardiac.

(b) **Keller-Killiani's Test:** Half a gram (0.5g) of plant extract was dissolved in 2ml glacial acetic acid. This was then underplayed with 1ml concentrated sulphuric acid. A brown ring obtained at the interphase, indicates the presence of deoxy-sugar, characteristic of cardiac glycoside. A violet ring appeared below the brown ring while in the acetic acid layer a greenish, ring formed just above the brown ring and gradually spread throughout this layer.

(c) **Lieberman's Test:** Half a gram (0.5g) of plant extract was added to 3mls of chloroform and filtered; 10 drops of acetic anhydride was added to the filtrate along with 2 drops of concentrated sulphuric acid. A pink colour at the interphase was a positive for terpenes while a bluish colour was the steroids.

Test for Phlobatanins

Half a gram (0.5g) of the plant extract is added with 3 drops of 40% formaldehyde, 6 drops of dilute HCl was also added to boiling and cool. A precipitate was formed, if positive and washed with hot water; this left a colourless residue after washing indicated the presence of phlobatanins.

Test for Deoxy-Sugar

Half a gram (0.5g) of the filtered plant extract was dissolved in 2ml of glacial acetic acid containing one drop of ferric chloride. It was then underplayed with 1ml of concentrated sulphuric acid (H₂SO₄). Violet ring observed which settled after few minutes was an indication of a positive test.

Alkaloidal Partitioning (Qualitative Test)

The methods of [21, 22] were used for the alkaloidal partitioning. The ethanolic extract of *P. amarus* was dissolved in 5% Hcl and partitioned successively with 50ml of chloroform (CHCl₃) with the aid of separating funnel to give aqueous fraction and chloroform fraction, respectively. The aqueous fraction was then made alkaline with ammonium hydroxide (NH₄OH) solution of pH 12 and subsequently partitioned with chloroform (CHCl₃) to give alkaloidal fractions.

Sensitivity Testing of Crude Ethanolic Leaf Extracts of *Phyllanthus amarus* on Uro-pathogens

The crude ethanolic extracts of *Phyllanthus amarus* were tested for antibacterial potency by the disc diffusion method [23, 24] using Oxoid- Mueller Hinton agar (Difco Laboratories, Detroit, Mich) supplemented with 2% NaCl. The Mueller – Hinton agar (MHA) was sterilized in flasks cooled to 45 – 50°C and then poured into sterilized Petri dishes. Sterile filter paper discs of 6 mm diameter were impregnated with extract solution of graded concentrations (20 mg/ml and 40 mg/ml) and then placed on to the agar plates which had previously been inoculated with the tested uropathogenic bacteria and the plates were incubated at 37°C for 24 hrs. Control experiments comprising streptomycin and Dimethyl sulphoxide (DMSO) were also set up. The diameters of the inhibitory zones were measured in millimeters. Assays were performed in triplicate and the data are shown as the mean \pm standard deviation (SD).

Sensitivity Testing of Alkaloidal Fractions of *Phyllanthus amarus* on Uro-pathogens

The alkaloidal fractions of *Phyllanthus amarus* was also tested for antibacterial potency by the disc diffusion method using Oxoid- Mueller Hinton agar supplemented with 2% NaCl. The Mueller – Hinton agar was sterilized in flasks cooled to 45 – 50°C and then poured into sterilized Petri dishes. Sterile filter paper discs of 6 mm diameter were impregnated with 20 mg/ml of the alkaloidal fractions and then placed on to the agar plates which had previously been inoculated with the tested uropathogenic bacteria. The plates were then incubated at 37°C for 24 hrs and the diameters of the inhibitory zones were measured in millimeters. Assays were performed in triplicate and the data are shown as the mean \pm standard deviation (SD).

Determination of Activity Index (A.I)

Activity Index (A.I) was calculated as the mean inhibition zone of sample (*P. amarus*) divided by the mean inhibition zone of the standard drug used (streptomycin).

$$\text{Activity Index} = \frac{\text{Mean inhibition zone of sample (P. amarus)}}{\text{Mean inhibition zone of the standard drug (Streptomycin)}}$$

Determination of Minimum Inhibitory concentration (MIC) and Minimum Bactericidal Concentration (MBC)

The Minimum Inhibitory Concentration (MIC) of crude ethanolic extracts of *Phyllanthus amarus* was determined for each of the uro-pathogens using micro broth method. Zero point five (0.5) ml each of the isolate was added to the following varying concentrations of the extracts: 5 mg/ml, 10 mg/ml, 20 mg/ml, 40 mg/ml and 80 mg/ml containing 2ml of nutrient broth. The cultures were then incubated at 37°C for 24 hrs. After incubation, the microbial growth was examined by observing for turbidity. The tube containing the least concentration of extract showing no visible sign of growth was considered as the minimum inhibitory concentration. To determine the MBC for each of the test isolate, 1ml of the broth was collected from the tubes that showed no growth and inoculated onto sterile nutrient agar. The plates were then incubated at 37°C for 24 hrs. After incubation the concentration that showed no visible growth was considered as the Minimum Bactericidal Concentration (MBC).



The results of preliminary phytochemical analysis of the ethanolic leaf extracts of *Phyllanthus amarus* revealed the presence of phyto-constituents such as alkaloids (+++), tannins (+++), saponins (++), flavonoids (++), cardiac

glycoside (+), free anthraquinones (++) , deoxy-Sugar test (+) and phlobatanins (+), while combined anthraquinones was not detected (Table 1). The results of the morphological and biochemical characteristics of the Gram positive (*Streptococcus* sp *Staphylococcus aureus*; Coagulase negative *Staphylococcus* sp and *Enterococcus faecalis*) and Gram negative bacteria (*Escherichia coli*, *Enterobacter* sp.; *Serratia marcescens*; *Klebsiella* sp and *Pseudomonas aeruginosa*) isolated from mid-stream urine samples are shown in Table 2.

There was no bacterial growth when ethanolic leave crude extracts of *Phyllanthus amarus* were plated out on Petri dishes containing nutrient agar and incubated at 37°C for 24hrs. Thus, indicated and confirmed the purity of the ethanolic leave crude extracts of *Phyllanthus amarus*. The results showed that ethanolic leave crude extracts of *Phyllanthus amarus* exhibited varying degrees of inhibitory effects against both Gram positive and Gram negative bacteria isolated from mid-stream urine samples and the zones of inhibition increased with the increase in concentrations of the ethanolic leave crude extracts of *Phyllanthus amarus*, thus, exhibiting concentration dependent activity. Ethanolic leave crude extracts of *Phyllanthus amarus* showed the highest mean zones of Inhibition (MM) \pm SD of 14.3 ± 1.0 mm and activity index 0.97 at 40.0 mgml^{-1} among the Gram positive bacteria, while the highest mean zones of Inhibition (MM) \pm SD of 14.5 ± 0.5 mm and activity index of 1.12 at 40.0 mgml^{-1} among the Gram negative (Tables 3 and 4). The results also showed that Coagulase negative *Staphylococcus* sp (CS03) was not sensitive to both 20.0 mgml^{-1} of crude extracts of *Phyllanthus amarus* and alkaloidal fractions. Among the Gram negative, *Enterobacter* sp (ES03) was not sensitive to 20.0 mgml^{-1} of crude extract of *Phyllanthus amarus*, alkaloidal fractions and streptomycin. The results showed that di-methyl sulphoxide (DMSO) exhibited no inhibition on all the isolates tested (Tables 3 and 4). Duncan's multiple range tests showed significant difference ($P < 0.05$) among the mean diameter inhibition zones for the ethanolic leave crude extracts of *Phyllanthus amarus*, flavonoids fraction and streptomycin.

The minimum inhibitory concentration and minimum bactericidal concentration concentrations of *Phyllanthus amarus* are shown in Figs 2 and 3. The results showed that minimum inhibitory concentration of 5mg/ml was observed with Coagulase negative *Staphylococcus* spp (CS01), *Enterococcus faecalis* (EF02) and *Escherichia coli* (EC03), while in *Streptococcus pyogenes* (SP02) and CON-*Staphylococcus* sp (CS03), the minimum bactericidal concentration of *Phyllanthus amarus* was 80 mg/ml (Figs 2 and 3).

Table 1: The Preliminary Phytochemical Screening of Ethanolic Leaf of *Phyllanthus amarus*

Bioactive Compounds	Inferences
Alkaloid	+++
Tannin test	+++
Saponins	
a. Frothing test	++
b. Sodium Bicarbonates test	++
Flavonoid	++
Cardiac glycoside	
a. Salkowski's test	+
b. Lieberman's test	+
c. Keller-killiani's test	+
Deoxy-Sugar test	+
Phlobatanins	+
Anthraquinones test	
a. Free Anthraquinones	++
b. Combined Anthraquinones	-

Keys: + = Present in small concentrations; ++ = Present in moderately high concentration; +++ = present in very high concentration; - = Not detected

Table 2: Morphological and Biochemical Characteristics of Bacteria Isolated from Mid-stream Urine Samples

Parameters	a	b	c	d	e	F	g	h	i
Grams reaction	+/cocci	+/cocci	+/cocci	-/rod	-/rod	+/cocci	-/rod	-r/rod	-/rod
Catalase test	-	+	+	-	-	-	-	-	-
Citrate test	-	-	-	-	-	-	+	+	-
Coagulase test	-	+	-	-	-	-	-	-	-
Motility	+	+	+	+	+	+	+	-	+
Indole test	-	-	-	+	-	-	-	-	-
Oxidase	-	-	-	-	-	-	-	-	+
Urease activity	-	-	-	-	-	-	-	+	-
Glucose	+	+	+	+	+	+	+	+	+
Lactose	-	-	-	+	+	-	-	+	-
Sucrose	-	-	-	-	-	-	+	+	-
Mannitol	+	+	+	+	+	+	+	+	+
Voges Proskauer	-	+	+	-	+	-	+	+	-

Keys - = negative; + = positive; a: *Streptococcus* sp; b: *Staphylococcus aureus*; c: *CON-Staphylococcus* sp d: *Escherichia coli*; e: *Enterobacter* sp; f: *Enterococcus faecalis*; g: *Serratia marcescens*; h: *Klebsiella* sp; i: *Pseudomonas aeruginosa*

Table 3: Antibacterial Activity of Crude Ethanolic Extracts of *Phyllanthus amarus* and Alkaloidal Fractions on Gram negative Uro-pathogens

Bacterial spp.	Code	Crude Extracts			Alkaloidal fractions			Streptomycin	DMSO
		20mg/ml	AI	40 mg/ml	AI	20 mg/ml	AI		
<i>Escherichia coli</i>	EC01	10.2 ± 0.5 ^b	0.68	14.0 ± 1.0 ^b	0.93	8.0 ± 2.0 ^a	5.33	15.0 ± 1.3 ^a	NZ
<i>Escherichia coli</i>	EC02	10.0 ± 1.2 ^b	0.81	10.0 ± 2.0 ^a	0.81	7.7 ± 1.0 ^a	0.62	12.4 ± 2.0 ^a	NZ
<i>Escherichia coli</i>	EC03	12.0 ± 10 ^b	0.93	14.5 ± 0.5 ^b	1.12	8.9 ± 2.5 ^a	0.68	12.9 ± 1.6 ^a	NZ
<i>Klebsiella</i> sp	KS01	10.0 ± 1.7 ^b	0.61	13.2 ± 0.5 ^b	0.80	8.1 ± 1.0 ^a	0.49	16.4 ± 2.0 ^b	NZ
<i>Klebsiella</i> sp	KS02	7.5 ± 1.3 ^a	0.47	9.9 ± 1.0 ^a	0.62	7.5 ± 0.1 ^a	0.47	16.0 ± 1.5 ^b	NZ
<i>Klebsiella</i> sp	KS03	8.3 ± 0.5 ^a	0.54	11.5 ± 1.5 ^a	0.74	7.9 ± 1.2 ^a	0.51	15.6 ± 0.4 ^a	NZ
<i>Pseudomonas aeruginosa</i>	PA01	9.2 ± 1.2 ^a	0.61	12.5 ± 2.5 ^a	0.82	8.1 ± 0.1 ^a	0.54	15.1 ± 2.0 ^a	NZ
<i>Pseudomonas aeruginosa</i>	PA02	10.2 ± 1.5 ^b	0.62	12.3 ± 0.5 ^a	0.75	9.1 ± 1.0 ^a	0.55	16.4 ± 2.2 ^b	NZ
<i>Pseudomonas aeruginosa</i>	PA03	9.0 ± 1.1 ^a	0.48	12.8 ± 1.1 ^a	0.68	7.2 ± 2.2 ^a	0.38	18.8 ± 1.0 ^b	NZ
<i>Serratia marcescens</i>	SM01	10.8 ± 1.5 ^b	0.65	14.2 ± 0.2 ^b	0.83	7.4 ± 1.5 ^a	0.43	17.1 ± 0.5 ^b	NZ
<i>Serratia marcescens</i>	SM02	10.3 ± 1.5 ^b	0.65	11.0 ± 1.5 ^a	0.65	8.2 ± 0.5 ^a	0.49	16.7 ± 1.0 ^b	NZ
<i>Serratia marcescens</i>	SM03	9.2 ± 1.8 ^a	0.66	11.5 ± 2.0 ^a	0.82	7.7 ± 1.0 ^a	0.55	14.0 ± 0.5 ^a	NZ
<i>Enterobacter</i> sp	ES01	7.5 ± 1.5 ^a	0.61	9.9 ± 1.0 ^a	0.81	7.1 ± 0.5 ^a	0.58	12.2 ± 1.6 ^a	NZ
<i>Enterobacter</i> sp	ES02	10.0 ± 1.5 ^b	-	12.0 ± 0.5 ^a	-	8.3 ± 1.2 ^a	-	NZ	NZ
<i>Enterobacter</i> sp	ES03	NZ	-	9.9 ± 1.0 ^a	-	NZ	-	NZ	NZ

Keys: AI: Activity Index; DMSO: Dimethyl Sulphoxide; NZ: No Zone of Inhibition. Each value represents the mean of three experiments and standard deviation. Means within the column followed by the same letter do not differ significantly as determined by Duncan's multiple range test ($P < 0.05$) among the treatment

Table 4: Antibacterial Activity of Ethanolic Extract of *Phyllanthus amarus* and Alkaloidal Fractions of Gram positive Uro-pathogens

Bacterial sp	Code	Crude Extracts			Alkaloidal fractions			Streptomycin	DMSO
		20 mg/ml	AI	40 mg/ml	AI	20 mg/ml	AI		
<i>Staphylococcus aureus</i>	SA01	8.0 ± 0.5 ^a	0.57	10.5 ± 1.5 ^a	0.75	7.0 ± 1.0 ^a	0.5	14.0 ± 2.0 ^a	NZ
<i>Staphylococcus aureus</i>	SA02	9.2 ± 1.0 ^a	0.56	12.5 ± 2.0 ^b	0.76	6.9 ± 2.1 ^a	0.42	16.4 ± 1.5 ^b	NZ
<i>Staphylococcus aureus</i>	SA03	9.0 ± 1.5 ^a	0.56	12.3 ± 0.1 ^b	0.77	8.4 ± 1.2 ^a	0.53	16.0 ± 0.2 ^a	NZ
<i>Streptococcus pyogenes</i>	SP01	7.0 ± 0.8 ^a	-	10.5 ± 0.5 ^a	-	NZ	-	NZ	NZ
<i>Streptococcus pyogenes</i>	SP02	9.8 ± 1.5 ^a	0.68	12.0 ± 0.1 ^b	0.83	7.6 ± 2.0 ^a	0.53	14.4 ± 2.6 ^a	NZ
<i>Streptococcus pyogenes</i>	SP03	9.4 ± 0.4 ^a	0.59	12.1 ± 0.2 ^b	0.76	9.2 ± 1.1 ^a	0.58	15.9 ± 1.0 ^b	NZ
CON- <i>Staphylococcus</i> sp	CS01	12.2 ± 0.5 ^b	0.59	14.0 ± 0.1 ^b	0.69	9.0 ± 0.5 ^a	0.44	20.4 ± 2.1 ^b	NZ
CON- <i>Staphylococcus</i> sp	CS02	10.8 ± 0.5 ^a	0.65	13.6 ± 1.0 ^b	0.82	8.6 ± 1.1 ^a	0.52	16.6 ± 1.0 ^b	NZ
CON- <i>Staphylococcus</i> sp	CS03	NZ	-	8.2 ± 0.2 ^a	0.79	NZ	-	10.4 ± 1.2 ^a	NZ
<i>Enterococcus faecalis</i>	EF01	10.2 ± 0.4 ^a	0.64	13.8 ± 1.2 ^b	0.86	7.4 ± 2.0 ^a	0.46	16.0 ± 2.1 ^b	NZ
<i>Enterococcus faecalis</i>	EF02	12.0 ± 1.1 ^b	0.82	14.3 ± 1.0 ^b	0.97	8.9 ± 0.5 ^a	0.61	14.7 ± 1.5 ^a	NZ

Key: AI: Activity Index; DMSO: Dimethyl Sulphoxide; NZ: No Zone of Inhibition. Each value represents the mean of three experiments and standard deviation. Means within the column followed by the same letter do not differ significantly as determined by Duncan's multiple range test ($P < 0.05$) among the treatment




Fig 2: Graphical representation of MIC and MBC of Gram positive uropathogenic bacteria




Fig 3: Graphical representation of MIC and MBC of Gram negative uropathogenic bacteria

DISCUSSION

Urinary tract infection is the largest single group of hospital-acquired infection and account for about 40–50% of the total nosocomial infections [25]. The occurrence of *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterococcus faecalis* and *Staphylococcus aureus* in the mid stream urine is in agreement with [26]. The defeat suffered by antibiotics such as penicillin, methicillin, vancomycin and other antibiotics has necessitated the search for valuable compounds that potentiate antibacterial activity on multidrug bacteria especially those that cause urinary tract infections. Preliminary phytochemical tests of ethanolic leaf extracts of *P. amarus* revealed the presence of anthraquinones, cardiac glycosides, saponins, tannins, alkaloids, flavonoids, which is in conformity with the earlier reports on *P. amarus* [17, 27]. The antimicrobial effect of plant extracts could be due to the presence of some of these phyto-constituents [28, 29]. The antibacterial activities of alkaloids have been reported by [28]

The secondary metabolites of plants exert antimicrobial activity through different mechanisms. Tannins form irreversible complexes with proline rich protein, resulting in the inhibition of cell protein synthesis and the flavonoids complex with extracellular- soluble proteins and with bacterial cell wall proteins while the lipophilic flavonoids exert antimicrobial activity by disrupting microbial cells membranes [30, 31]. *P. amarus* ethanolic extracts tested were active against both Gram-positive bacteria and Gram-negative bacteria, suggesting a broader spectrum activity of the plant. The degree of susceptibilities of the uro-pathogenic Gram positive and Gram negative bacteria to *P. amarus* ethanolic extracts may be as a result of the physical and chemical compositions of their cell walls.

CONCLUSION

There is a need to consider the use of *P. amarus* ethanolic extracts and its alkaloidal fractions that have shown some measures of antibacterial potency, judging by the antibacterial activity, activity index, minimum inhibitory concentration and minimum bactericidal concentration in the treatment of urinary tract infection caused by bacteria.

Acknowledgements

The authors greatly acknowledge the assistance of Dr. Felix Ogbemudia of Department of Botany and Ecological Studies Akwa Ibom State.

REFERENCES

- [1] Akinjogunla, O. J., Odeyemi, A. T. and Olasehinde, G. I. *Journal of American Science*, **2010b**, 6(12):1674-1681p
- [2] Stamm, W. E. and Norrby, S. R. *Journal of Infectious Diseases*, **2001**, 183(1): 51-4p
- [3] Hvidberg, H. Struve, H. C., Krogfelt, K. A., Christensen, N. Rasmussen S. N. and Frimodt, M. *Antimicrobiol Agents Chemotherapy*, **2000**, 44: 156-163p.
- [4] Manges, A.R., Natarajan, P., Solberg, O.D., Dietrich, P.S. and Riley, L.W. *Epidemiology and Infections*, **2006**, 134: 425– 431p.
- [5] Akram, M., Shahid, M. and Khan, A. *Annals of Clinical Microbiology and Antimicrobial*. **2007**, 6(4):1-7p.
- [6] Saonua, P., Hiransuthikul, N., Suankratay, C., Malathum, K. and Danchaivijitr. S. *Asian Biomed*, **2008**, 2: 485-491.
- [7] Noor, N., Ajaz, M., Rasoxl, S. A. and Pirzada, Z. A. Urinary tract infections associated with multi-drug resistant enteric bacilli: Characterization and genetical studies, **2004**, 221-225p.
- [8] Harding, G. and Ronald, R. *International Journal of Antimicrobial Agents*, **1994**, 4: 83–88p
- [9] Davies, J. *Science*, **1994**, 264: 375-382p.
- [10] Martino, P.D., Gagniere, H., Berry, H. and Bret, L. *Microbiology and Infection*. **2002**, 4: 613-620p.
- [11] Sofowora, A. *Medicinal plants and Traditional Medicine in Africa* Spectrum Books Limited. Ibadan. **2006**, 150-153p.
- [12] Iwu, M. M. In: Hand Book of African Medicinal CRC Press Inc, Florida. **1993**, 309 - 330p.
- [13] Cragg, G. M., Boyd, M. R., Khanna, R. Kneller, R. and Mays, T. D. *Pure and Applied Chemistry*. **1999**, 71: 1619-1633p.
- [14] Bharatiya, V. B. In: India Tafa Press, Bombay: **1992**, 235-237p
- [15] Odetola, A. A. and Akojenu, S. M. *Africa Journal of Medical Science*. **2000**, 29: 119 –122p.
- [16] Kassuyaa, C. A., Silerstre, A. A., Rehder, V., Calixto, J. B. *Eur. J Pharm*, **2003**, 478: 145-153p

-
- [17] Oluwafemi, F. and Debiri, F. *Afr. J. Biomed. Res.*, **2008**, 11: 215-219p
- [18] Holt, J.G., Krieg, N.R., Sneath, P.H.A., Stately, J.T., Williams, S.T. 1994. *Bergey's Manual of Determinative Bacteriology*, (9th edn), Baltimore, Williams and Wilkins, **1994**, 787p.
- [19] Cowan, S.T. and Steel, K.J. *Manual for the Identification of Medical Bacteria* (4th Edition). Cambridge University Press. London. **1985**, 217p.
- [20] Cheesbrough, M. (2006). In: *District Laboratory Practical in Tropical Countries* Part 2 (2nd edition). Hong Kong: Shek Tong. **2006**, 398-412, 106-115 p.
- [21] Harborne, J.B. (1998). *Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis*. (3rd Edition). Chapman and Hall Co., New York. **1998**, 88-190p
- [22] Trease, A. and Evans, W. C. *A textbook of Pharmacognosy* (14th edition) Bailliere Tindall London, **2002**, 76-84p.
- [23] NCCLS. Performance standards for antimicrobial susceptibility testing, fourteenth informational supplement. **2004**. M100 – S14. NCCLS, Wayne, P. A. USA.
- [24] Nair, R., Kalariya, T. and Sumitra, C. *Turkish Journal of Biology*. **2005**, 29: 9-47p
- [25] Hassan, S. A., Jamal, S.A. and Kamal, M. *Journal of Basic and Applied Sciences*, **2011**, 7 (1), 39-43p
- [26] Saleem, M. and Daniel, B. *Int. J. Emerg. Sci.*, **2011**, 1(2):133-142p
- [27] Akinjogunla, O. J., Eghafona, N. O., Enabulele, I. O., Mboto, C. I. and Ogbemudia, F. O. *African Journal of Pharmacy and Pharmacology*, **2010a**, 4(6): 402-407p
- [28] Ebana, R.U.B., Madunagu, B.E. and Ekpe, E.D. *J. Appl. Bacteriol.*, **2005**, 71: 398- 401p.
- [29] Cushnie, T.P. and Lamb, A.J. *Int. J. Antimicrobial Agents*, **2005**, 26: 343
- [30] Tsuchiya, H.M.S., Miyazaki, T. and Fujiwara S. *J. Ethnopharmacol.*, **1996**, 50: 27- 34p.
- [31] Olowusulu, A.K. and Ibrahim, Y.K.E. *West Afr. J. Biol. Sci.*, **2006**, 3(5): 21-26p.